Palisade Bio Inc. Stock
Palisade Bio Inc. Stock
Our community is currently high on Palisade Bio Inc. with 5 Buy predictions and 1 Sell predictions.
With a target price of 21 € there is potential for a 6054.75% increase which would mean more than doubling the current price of 0.34 € for Palisade Bio Inc..
Our community identified positive and negative aspects for Palisade Bio Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Palisade Bio Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Palisade Bio Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Palisade Bio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Palisade Bio Inc. | - | - | - | - | - | - | - |
| Rockwell Medical Inc. | -0.650% | -5.576% | -1.316% | -60.860% | 16.408% | -46.062% | -92.089% |
| Pacira Pharmaceuticals | -0.510% | -7.477% | -7.477% | 11.864% | -8.333% | -41.071% | -65.565% |
| Twist Bioscience Corp | 4.230% | 11.475% | 23.824% | -25.377% | 17.199% | 33.224% | -75.642% |
Comments
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Clear Str Llc to a "strong-buy" rating.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat